Clinical & Scientific

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

With its Madsen Mine now in production, West Red Lake Gold turns to a past-producing legend, signaling a methodical strategy to build a multi-asset gold empire.

Light AI's smartphone diagnostic tool enters a crucial New Zealand study, but can its innovative tech overcome financial pressures and regulatory hurdles?

Nordicus Partners reveals promising data for gum disease and oral lesions, betting its future on a unique Nordic acquisition strategy and a Nasdaq uplisting.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Osisko Development's new high-grade gold intercepts at its Cariboo project aren't just a find; they're a strategic move to optimize a major new mine.